Newsbenzinga
Verastem Oncology Announces Presentation Of Phase 2 Biomarker Analysis For Avutometinib Plus Defactinib In Low-Grade Serous Ovarian Cancer
· Published
Article summary
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…